Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: November 09, 2012
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Osaka Securities Exchange containing financial results for the quarter ended September 30, 2012. This filing serves as Regulation FD disclosure, noting that the Tanshin is substantially the same as the Form 10-Q for the same period, with supplemental information regarding full-year 2012 estimates.
Key Financial Metrics and Guidance
The filing provides updated full-year estimates for the fiscal year ending December 31, 2012. The Company has not changed its previously reported estimates from August 10, 2012.
| Metric | Full Year 2012 Estimate |
|---|---|
| Revenues | $864,000 |
| Operating Loss | $11,006,000 |
| Net Loss | $10,993,000 |
| Expected Basic and Diluted Loss Per Share | $0.68 |
Note: The loss per share calculation uses a weighted average of 16,145,000 shares. The filing does not provide specific data for cash flow, debt, or liquidity positions for the quarter or year-to-date.
Material Changes and Outlook
Guidance Update: There are no material changes to the full-year 2012 financial estimates compared to the prior forecast issued on August 10, 2012.
Supplementary Information: The Japanese report includes financial statements denominated in Japanese yen, translated at a rate of 79.66 JPY per USD (as of October 31, 2012).
Risks, Contingencies, and Management Commentary
Management emphasizes that the estimates are based on assumptions subject to significant risks and uncertainties. Independent auditors have not compiled or reviewed these forecasted results. Key risk factors identified include:
- Uncertainties inherent in clinical trials, product development, and commercialization.
- Risks regarding regulatory approval and intellectual property rights.
- Reliance on third parties for clinical trials and manufacturing.
- Potential delays or cost increases in clinical trial execution.
- Risks related to the Company's joint venture in China and collaborations.
- Availability of funds to complete product development and the ability to raise capital.
The Company disclaims any obligation to update these forward-looking statements unless required by law.
Investor Verification Checklist
- Verify the actual Form 10-Q for the quarter ended September 30, 2012, to confirm quarterly performance details not explicitly listed in this 8-K.
- Review the Company's Annual Report on Form 10-K for the year ended December 31, 2011, for detailed risk factors referenced in this filing.
- Monitor the Company's capital raising activities given the projected net loss of approximately $11 million and reliance on external funding.
- Confirm the status of clinical trials and the China joint venture, as these are cited as primary drivers of potential variance from estimates.